What is the dosage of Elrexfio?

Elrexfio is available in 2 dosages, including 40 mg/ml Injection 1.1 ml and 40 mg/ml Injection 1.9 ml

What does Elrexfio treat?

Elrexfio treats Multiple Myeloma

How is Elrexfio administered?

Elrexfio is administered as a Injectable

Last Update: April 08, 2025

Elrexfio

(elranatamab-bcmm)

Dosage & Administration

	ELREXFIO Dosing Schedule
Dosing Schedule	Day	ELREXFIO Dose
* Responders only week 25 onward.
Step-up Dosing Schedule	Day 1	Step-up dose 1	12 mg
	Day 4	Step-up dose 2	32 mg
	Day 8	First treatment dose	76 mg
Weekly Dosing Schedule	One week after first treatment dose and weekly thereafter through week 24	Subsequent treatment doses	76 mg
Biweekly (Every 2 Weeks) Dosing Schedule *	Week 25 and every 2 weeks thereafter	Subsequent treatment doses	76 mg

* Patients should be hospitalized for 48 hours after administration of the first step-up dose, and for 24 hours after administration of the second step-up dose.
* For subcutaneous injection only.
* Administer pre-treatment medications as recommended.
* See Full Prescribing Information for instructions on preparation and administration.

Elrexfio Prescribing Information

•: Cytokine Release Syndrome (CRS), including life-threatening or fatal reactions, can occur in patients receiving ELREXFIO. Initiate treatment with ELREXFIO step-up dosing schedule to reduce the risk of CRS. Withhold ELREXFIO until CRS resolves or permanently discontinue based on severity [see Dosage and Administration (2.2, 2.5), Warnings and Precautions (5.1)].
•: Neurologic toxicity, including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), and serious and life-threatening reactions, can occur in patients receiving ELREXFIO. Monitor patients for signs and symptoms of neurologic toxicity, including ICANS, during treatment. Withhold ELREXFIO until the neurologic toxicity resolves or permanently discontinue based on severity [see Dosage and Administration (2.5), Warnings and Precautions (5.2)].
•: Because of the risk of CRS and neurologic toxicity, including ICANS, ELREXFIO is available only through a restricted program under a Risk Evaluation and Mitigation Strategy (REMS) called ELREXFIO REMS [see Warnings and Precautions (5.3)].

ELREXFIO is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.

This indication is approved under accelerated approval based on response rate and durability of response [see Clinical Studies (14)]. Continued approval for this indication may be contingent upon verification of clinical benefit in a confirmatory trial(s).

Important Dosing Information

Administer ELREXFIO subcutaneously according to the step-up dosing schedule to reduce the incidence and severity of cytokine release syndrome (CRS).

Administer pre-treatment medications prior to each dose in the ELREXFIO step-up dosing schedule, which includes step-up dose 1, step-up dose 2, and the first treatment dose as recommended [see Dosage and Administration (2.2, 2.3)].

ELREXFIO should only be administered by a qualified healthcare professional with appropriate medical support to manage severe reactions such as CRS and neurologic toxicity, including ICANS [see Warnings and Precautions (5.1, 5.2)].

Due to the risk of CRS, patients should be hospitalized for 48 hours after administration of the first step-up dose, and for 24 hours after administration of the second step-up dose.

Recommended Dosage

For subcutaneous injection only.

The recommended dosing schedule for ELREXFIO is provided in Table 1. The recommended dosages of ELREXFIO subcutaneous injection are: step-up dose 1 of 12 mg on Day 1, step-up dose 2 of 32 mg on Day 4, followed by the first treatment dose of 76 mg on Day 8, and then 76 mg weekly thereafter through week 24.

For patients who have received at least 24 weeks of treatment with ELREXFIO and have achieved a response [partial response (PR) or better] and maintained this response for at least 2 months, the dose interval should transition to an every two-week schedule.

Continue treatment with ELREXFIO until disease progression or unacceptable toxicity.

Table 1. ELREXFIO Dosing Schedule
Note: See Table 2 for recommendations on restarting ELREXFIO after dose delays.
* Administer pre-treatment medications prior to each dose in the ELREXFIO step-up dosing schedule, which includes step-up dose 1, step-up dose 2, and the first treatment dose [see Dosage and Administration (2.3)]. † A minimum of 2 days should be maintained between step-up dose 1 (12 mg) and step-up dose 2 (32 mg). ‡ A minimum of 3 days should be maintained between step-up dose 2 (32 mg) and the first treatment (76 mg) dose. § A minimum of 6 days should be maintained between treatment doses.
Dosing Schedule	Day	ELREXFIO Dose
Step-up Dosing Schedule	Day 1 *	Step-up dose 1	12 mg
	Day 4 * †	Step-up dose 2	32 mg
	Day 8 * ‡	First treatment dose	76 mg
Weekly Dosing Schedule	One week after first treatment dose and weekly thereafter § through week 24	Subsequent treatment doses	76 mg
Biweekly (Every 2 Weeks) Dosing Schedule *Responders only week 25 onward	Week 25 and every 2 weeks thereafter §	Subsequent treatment doses	76 mg

Recommended Pre-treatment Medications

Administer the following pre-treatment medications approximately 1 hour before the first three doses of ELREXFIO in the step-up dosing schedule, which includes step-up dose 1, step-up dose 2, and the first treatment dose as described in Table 1 to reduce the risk of CRS [see Warnings and Precautions (5.1)]:

•: acetaminophen (or equivalent) 650 mg orally
•: dexamethasone (or equivalent) 20 mg orally or intravenously
•: diphenhydramine (or equivalent) 25 mg orally

Restarting ELREXFIO After Dosage Delay

If a dose of ELREXFIO is delayed, restart therapy based on the recommendations listed in Table 2 and resume the dosing schedule accordingly [see Dosage and Administration (2.2)]. Administer pre-treatment medications as indicated in Table 2.

Table 2. Recommendation for Restarting Therapy with ELREXFIO After Dosage Delay
* Administer pre-treatment medications prior to the ELREXFIO dose [see Dosage and Administration (2.3)]. † Consider benefit-risk of restarting ELREXFIO in patients who require a dose delay of more than 42 days due to an adverse reaction.
Last Dose Administered	Time Since the Last Dose Administered	Action for Next Dose
Step-up dose 1 (12 mg)	2 weeks or less (≤14 days)	Restart ELREXFIO at step-up dose 2 (32 mg). * If tolerated, increase to 76 mg 4 days later.
Step-up dose 1 (12 mg)	Greater than 2 weeks (>14 days)	Restart ELREXFIO step-up dosing schedule at step-up dose 1 (12 mg). *
Step-up dose 2 (32 mg)	2 weeks or less (≤14 days)	Restart ELREXFIO at 76 mg. *
	Greater than 2 weeks to less than or equal to 4 weeks (15 days to ≤28 days)	Restart ELREXFIO at step-up dose 2 (32 mg). * If tolerated, increase to 76 mg 1 week later.
	Greater than 4 weeks (>28 days)	Restart ELREXFIO step-up dosing schedule at step-up dose 1 (12 mg). *
Any treatment dose (76 mg)	6 weeks or less (≤42 days)	Restart ELREXFIO at 76 mg.
	Greater than 6 weeks to less or equal to 12 weeks (43 days to ≤84 days) †	Restart ELREXFIO at step-up dose 2 (32 mg). * If tolerated, increase to 76 mg 1 week later.
	Greater than 12 weeks (>84 days) †	Restart ELREXFIO step-up dosing schedule at step-up dose 1 (12 mg). *

Dosage Modifications for Adverse Reactions

Dosage reductions of ELREXFIO are not recommended.

Dosage delays may be required to manage toxicities related to ELREXFIO [see Warnings and Precautions (5)]. Recommendations on restarting ELREXFIO after a dose delay are provided in Table 2.

See Table 3 and Table 4 for recommended actions for adverse reactions of CRS and ICANS, respectively. See Table 5 for recommended actions for neurologic toxicity excluding ICANS and Table 6 for recommended actions for other adverse reactions following administration of ELREXFIO. Consider further management per current practice guidelines.

Management of CRS, Neurologic Toxicity Including ICANS

Cytokine Release Syndrome (CRS)

Management recommendations for CRS are summarized in Table 3.

Identify CRS based on clinical presentation [see Warnings and Precautions (5.1)]. Evaluate and treat other causes of fever, hypoxia, and hypotension.

If CRS is suspected, withhold ELREXFIO until CRS resolves. Manage CRS according to the recommendations in Table 3 and consider further management per current practice guidelines. Administer supportive therapy for CRS, which may include intensive care for severe or life-threatening CRS. Consider laboratory testing to monitor for disseminated intravascular coagulation (DIC), hematology parameters, as well as pulmonary, cardiac, renal, and hepatic function.

Table 3. Recommendations for Management of CRS
* Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading criteria for CRS. † Attributed to CRS. Fever may not always be present concurrently with hypotension or hypoxia as it may be masked by interventions such as antipyretics or anti-cytokine therapy. ‡ See Table 2 for recommendations on restarting ELREXFIO after dose delays. § Low-flow nasal cannula is ≤6 L/min, and high-flow nasal cannula is >6 L/min.
Grade *	Presenting Symptoms	Actions
Grade 1	Temperature ≥100.4 °F (38 °C) †	• Withhold ELREXFIO until CRS resolves. ‡ • Administer pretreatment medications prior to next dose of ELREXFIO.
Grade 2	Temperature ≥100.4 °F (38 °C) with either: • Hypotension responsive to fluid and not requiring vasopressors, and/or • Oxygen requirement of low-flow nasal cannula § or blow-by	• Withhold ELREXFIO until CRS resolves. ‡ • Monitor patients daily for 48 hours following the next dose of ELREXFIO. Instruct patients to remain within proximity of a healthcare facility, and consider hospitalization. • Administer pretreatment medications prior to next dose of ELREXFIO.
Grade 3 (First occurrence)	Temperature ≥100.4 °F (38 °C) with either: • Hypotension requiring one vasopressor with or without vasopressin, and/or • Oxygen requirement of high-flow nasal cannula §, facemask, non-rebreather mask, or Venturi mask	• Withhold ELREXFIO until CRS resolves. ‡ • Provide supportive therapy, which may include intensive care. • Patients should be hospitalized for 48 hours following the next dose of ELREXFIO. • Administer pretreatment medications prior to next dose of ELREXFIO.
Grade 3 (Recurrent)	Temperature ≥100.4 °F (38 °C) with either: • Hypotension requiring one vasopressor with or without vasopressin, and/or • Oxygen requirement of high-flow nasal cannula §, facemask, non-rebreather mask, or Venturi mask	• Permanently discontinue therapy with ELREXFIO. • Provide supportive therapy, which may include intensive care.
Grade 4	Temperature ≥100.4 °F (38 °C) with either: • Hypotension requiring multiple vasopressors (excluding vasopressin), and/or • Oxygen requirement of positive pressure (e.g., continuous positive airway pressure [CPAP], bilevel positive airway pressure [BiPAP], intubation, and mechanical ventilation)	• Permanently discontinue therapy with ELREXFIO. • Provide supportive therapy, which may include intensive care.

Neurologic Toxicity Including ICANS

Management recommendations for ICANS and neurologic toxicity are summarized in Table 4 and Table 5.

At the first sign of neurologic toxicity, including ICANS, withhold ELREXFIO and consider neurology evaluation. Rule out other causes of neurologic symptoms. Provide supportive therapy, which may include intensive care, for severe or life-threatening neurologic toxicities, including ICANS [see Warnings and Precautions (5.2)]. Manage ICANS according to the recommendations in Table 4 and consider further management per current practice guidelines.

Table 4. Recommendations for Management of ICANS
* Based on American Society for Transplantation and Cellular Therapy (ASTCT) 2019 grading criteria for ICANS. † Management is determined by the most severe event, not attributable to any other cause. ‡ If patient is arousable and able to perform Immune Effector Cell-Associated Encephalopathy (ICE) Assessment, assess: Orientation (oriented to year, month, city, hospital = 4 points); Naming (name 3 objects, e.g., point to clock, pen, button = 3 points); Following Commands (e.g., “show me 2 fingers” or “close your eyes and stick out your tongue” = 1 point); Writing (ability to write a standard sentence = 1 point); and Attention (count backwards from 100 by ten = 1 point). If patient is unarousable and unable to perform ICE Assessment (Grade 4 ICANS) = 0 points. § Not attributable to any other cause. ¶ See Table 2 for recommendations on restarting ELREXFIO after dose delays. # All references to dexamethasone administration are dexamethasone or equivalent medications.
Grade *	Presenting Symptoms †	Actions
Grade 1	ICE score 7-9 ‡ Or depressed level of consciousness §: awakens spontaneously.	• Withhold ELREXFIO until ICANS resolves. ¶ • Monitor neurologic symptoms and consider consultation with a neurologist and other specialists for further evaluation and management. • Consider non-sedating, anti-seizure medications (e.g., levetiracetam) for seizure prophylaxis.
Grade 2	ICE score 3-6 ‡ Or depressed level of consciousness §: awakens to voice.	• Withhold ELREXFIO until ICANS resolves. ¶ • Administer dexamethasone # 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper. • Monitor neurologic symptoms and consider consultation with a neurologist and other specialists for further evaluation and management. • Consider non-sedating, anti-seizure medications (e.g., levetiracetam) for seizure prophylaxis. • Monitor patients daily for 48 hours following the next dose of ELREXFIO. Instruct patients to remain within proximity of a healthcare facility, and consider hospitalization.
Grade 3 (First occurrence)	ICE score 0-2 ‡ or depressed level of consciousness §: awakens only to tactile stimulus, or seizures §, either: • any clinical seizure, focal or generalized, that resolves rapidly, or • non-convulsive seizures on electroencephalogram (EEG) that resolve with intervention, or raised intracranial pressure: focal/local edema on neuroimaging §	• Withhold ELREXFIO until ICANS resolves. ¶ • Administer dexamethasone # 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper. • Monitor neurologic symptoms and consider consultation with a neurologist and other specialists for further evaluation and management. • Consider non-sedating, anti-seizure medications (e.g., levetiracetam) for seizure prophylaxis. • Provide supportive therapy, which may include intensive care. • Patients should be hospitalized for 48 hours following the next dose of ELREXFIO.
Grade 3 (recurrent)	ICE score 0-2 ‡ or depressed level of consciousness §: awakens only to tactile stimulus, or seizures §, either: • any clinical seizure, focal or generalized, that resolves rapidly, or • non-convulsive seizures on electroencephalogram (EEG) that resolve with intervention, or raised intracranial pressure: focal/local edema on neuroimaging §	• Permanently discontinue ELREXFIO. • Administer dexamethasone # 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper. • Monitor neurologic symptoms and consider consultation with a neurologist and other specialists for further evaluation and management. • Consider non-sedating, anti-seizure medications (e.g., levetiracetam) for seizure prophylaxis. • Provide supportive therapy, which may include intensive care.
Grade 4	ICE score 0 ‡ Or, depressed level of consciousness § either: • patient is unarousable or requires vigorous or repetitive tactile stimuli to arouse, or • stupor or coma, or seizures §, either: • life-threatening prolonged seizure (>5 minutes), or • repetitive clinical or electrical seizures without return to baseline in between, or motor findings §: • deep focal motor weakness such as hemiparesis or paraparesis, or raised intracranial pressure/cerebral edema §, with signs/symptoms such as: • diffuse cerebral edema on neuroimaging, or • decerebrate or decorticate posturing, or • cranial nerve VI palsy, or • papilledema, or • Cushing’s triad	• Permanently discontinue ELREXFIO. • Administer dexamethasone # 10 mg intravenously every 6 hours. Continue dexamethasone use until resolution to Grade 1 or less, then taper. • Alternatively, consider administration of methylprednisolone 1,000 mg per day intravenously for 3 days. • Monitor neurologic symptoms and consider consultation with a neurologist and other specialists for further evaluation and management. • Consider non-sedating, anti-seizure medications (e.g., levetiracetam) for seizure prophylaxis. • Provide supportive therapy, which may include intensive care.

Table 5. Recommendations for Management of Neurologic Toxicity, Excluding ICANS
Adverse Reaction	Severity	Actions
Neurologic Toxicity (excluding ICANS)	Grade 1	• Withhold ELREXFIO until neurologic toxicity symptoms resolve or stabilize.
	Grade 2 Grade 3 (First occurrence)	• Withhold ELREXFIO until neurologic toxicity symptoms improve to Grade 1 or less. • Provide supportive therapy.
	Grade 3 (Recurrent) Grade 4	• Permanently discontinue ELREXFIO. • Provide supportive therapy, which may include intensive care.

Table 6. Recommended Dosage Modifications for Other Adverse Reactions
* See Table 2 for recommendations on restarting ELREXFIO after dose delays. † Based on National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 5.0.
Adverse Reactions	Severity	Actions
Hematologic Adverse Reactions [see Warnings and Precautions (5.5)]	Absolute neutrophil count less than 0.5 x 109/L	• Withhold ELREXFIO until absolute neutrophil count is 0.5 x 109/L or higher. *
	Febrile neutropenia	• Withhold ELREXFIO until absolute neutrophil count is 1 x 109/L or higher and fever resolves. *
	Hemoglobin less than 8 g/dL	• Withhold ELREXFIO until hemoglobin is 8 g/dL or higher. *
	Platelet count less than 25,000/mcL Platelet count between 25,000/mcL and 50,000/mcL with bleeding	• Withhold ELREXFIO until platelet count is 25,000/mcL or higher and no evidence of bleeding. *
Infections and Other Non-hematologic Adverse Reactions † [see Warnings and Precautions (5.4, 5.6) and Adverse Reactions (6.1)]	Grade 3	• Withhold ELREXFIO until adverse reaction improves to ≤Grade 1 or baseline. *
	Grade 4	• Consider permanent discontinuation of ELREXFIO. • If ELREXFIO is not permanently discontinued, withhold subsequent treatment doses of ELREXFIO (e.g., doses administered after ELREXFIO step-up dosing schedule) until adverse reaction improves to Grade 1 or less.

Preparation and Administration Instructions

ELREXFIO is intended for subcutaneous use by a healthcare provider only.

ELREXFIO should be administered by a healthcare provider with adequate medical personnel and appropriate medical equipment to manage severe reactions, including CRS and neurologic toxicity, including ICANS [see Warnings and Precautions (5.1, 5.2)].

ELREXFIO 76 mg/1.9 mL (40 mg/mL) vial and 44 mg/1.1 mL (40 mg/mL) vial are supplied as ready-to-use solution that do not need dilution prior to administration.

ELREXFIO is a clear to slightly opalescent, and colorless to pale brown liquid solution. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not administer if solution is discolored or contains particulate matter.

Use aseptic technique to prepare and administer ELREXFIO.

Preparation

ELREXFIO vials are for one-time use in a single patient and do not contain any preservatives.

Prepare ELREXFIO following the instructions below (see Table 7) depending on the required dose. Use a 44 mg/1.1 mL (40 mg/mL) single-dose vial for step-up dose 1 or step-up dose 2.

Table 7. Injection Volumes
Total Dose (mg)	Volume of Injection
12 mg	0.3 mL
32 mg	0.8 mL
76 mg	1.9 mL

Remove the appropriate strength ELREXFIO vial from refrigerated storage 2 °C to 8 °C (36 °F to 46 °F)]. Once removed from refrigerated storage, equilibrate ELREXFIO to ambient temperature [15 °C to 30 °C (59 °F to 86 °F)]. Do not warm ELREXFIO in any other way.

Withdraw the required injection volume of ELREXFIO from the vial into an appropriately sized syringe with stainless steel injection needles (30G or wider) and polypropylene or polycarbonate syringe material. Discard unused portion.

Administration

Inject the required volume of ELREXFIO into the subcutaneous tissue of the abdomen (preferred injection site). Alternatively, ELREXFIO may be injected into the subcutaneous tissue at other sites (e.g., thigh).

Do not inject into tattoos or scars or areas where the skin is red, bruised, tender, hard or not intact.

Storage of Prepared Syringe

If the prepared dosing syringe is not used immediately, store syringe between 2 °C (36 °F) to 30 °C (86 °F) for a maximum of 4 hours.

Pregnancy

Risk Summary

Based on the mechanism of action, ELREXFIO may cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available data on the use of ELREXFIO in pregnant women to evaluate for a drug associated risk. No animal reproductive or developmental toxicity studies have been conducted with ELREXFIO. Elranatamab-bcmm causes T-cell activation and cytokine release; immune activation may compromise pregnancy maintenance. In addition, based on the finding of B-cell depletion in non-pregnant animals, elranatamab-bcmm can cause B-cell lymphocytopenia in infants exposed to elranatamab-bcmm in-utero. Human immunoglobulin (IgG) is known to cross the placenta after the first trimester of pregnancy; therefore, elranatamab-bcmm has the potential to be transmitted from the mother to the developing fetus. Advise women of the potential risk to the fetus.

ELREXFIO is associated with hypogammaglobulinemia, therefore, assessment of immunoglobulin levels in newborns of mothers treated with ELREXFIO should be considered.

In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Lactation

Risk Summary

There are no data on the presence of elranatamab-bcmm in human milk, the effects on the breastfed child, or the effects on milk production. Maternal IgG is known to be present in human milk.

Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with ELREXFIO and for 4 months after the last dose.

Females and Males of Reproductive Potential

ELREXFIO may cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

Pregnancy Testing

Verify the pregnancy status of females of reproductive potential prior to initiating treatment with ELREXFIO.

Contraception

Females

Advise females of reproductive potential to use effective contraception during treatment and for 4 months after the last dose of ELREXFIO.

Pediatric Use

The safety and effectiveness of ELREXFIO in pediatric patients have not been established.

Geriatric Use

Of the 183 patients with relapsed or refractory multiple myeloma treated with ELREXFIO in MagnetisMM-3 at the recommended dosage, 62% were 65 years of age or older, and 19% were 75 years of age or older. No overall differences in safety or effectiveness were observed in patients 65-74 years of age compared to younger patients. Clinical studies did not include sufficient numbers of patients 75 years of age or older to determine whether they respond differently from younger patients.

Cytokine Release Syndrome (CRS)

ELREXFIO can cause CRS, including life-threatening or fatal reactions [see Adverse Reactions (6.1)].

In the clinical trial, CRS occurred in 58% of patients who received ELREXFIO at the recommended dosing schedule [see Dosage and Administration (2.2)], with Grade 1 CRS in 44% of patients, Grade 2 CRS in 14% of patients, and Grade 3 CRS in 0.5% of patients. Recurrent CRS occurred in 13% of patients. Most patients experienced CRS after the first step-up dose (43%) or the second step-up dose (19%), with 7% of patients having CRS after the first treatment dose and 1.6% of patients after a subsequent dose. The median time to onset of CRS was 2 (range: 1 to 9) days after the most recent dose, with a median duration of 2 (range: 1 to 19) days.

Clinical signs and symptoms of CRS may include, but are not limited to, fever, hypoxia, chills, hypotension, tachycardia, headache, and elevated liver enzymes.

Initiate therapy according to the ELREXFIO step-up dosing schedule to reduce risk of CRS and monitor patients following administration of ELREXFIO accordingly [see Dosage and Administration (2.2, 2.5)]. Administer pre-treatment medications prior to each dose in the step-up dosing schedule to reduce risk of CRS [see Dosage and Administration (2.3)].

Counsel patients to seek medical attention should signs or symptoms of CRS occur. At the first sign of CRS, evaluate patients immediately for hospitalization. Manage CRS according to the recommendations and consider further management per current practice guidelines. Withhold or permanently discontinue ELREXFIO based on severity [see Dosage and Administration (2.5)].

ELREXFIO is available only through a restricted program under a REMS [see Warnings and Precautions (5.3)].

Neurologic Toxicity, Including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

ELREXFIO can cause serious or life-threatening neurologic toxicity, including ICANS [see Adverse Reactions (6.1)].

In the clinical trial, neurologic toxicity occurred in 59% of patients who received ELREXFIO at the recommended dosing schedule [see Dosage and Administration (2.2)], with Grade 3 or 4 neurologic toxicity occurring in 7% of patients. Neurologic toxicities included headache (18%), encephalopathy (15%), motor dysfunction (13%), sensory neuropathy (13%), and Guillain-Barré Syndrome (0.5%).

In the clinical trial, ICANS occurred in 3.3% of patients who received ELREXFIO at the recommended dosing schedule [see Dosage and Administration (2.2)]. Most patients had ICANS after the first step-up dose (2.7%), 1 (0.5%) patient had ICANS after the second step-up dose and 1 (0.5%) patient had ICANS after subsequent dose(s). Recurrent ICANS occurred in 1.1% of patients. The median time to onset was 3 (range: 1 to 4) days after the most recent dose, with a median duration of 2 (range: 1 to 18) days. The most frequent clinical manifestations of ICANS included a depressed level of consciousness and Grade 1 or Grade 2 Immune Effector Cell-Associated Encephalopathy (ICE) scores. The onset of ICANS can be concurrent with CRS, following resolution of CRS, or in the absence of CRS.

Counsel patients to seek medical attention should signs or symptoms of neurologic toxicity occur. Monitor patients for signs and symptoms of neurologic toxicities during treatment with ELREXFIO. At the first sign of neurologic toxicity, including ICANS, evaluate and treat patients immediately based on severity. Withhold or permanently discontinue ELREXFIO based on severity per recommendations [see Dosage and Administration (2.5)] and consider further management per current practice guidelines.

Due to the potential for neurologic toxicity including ICANS, patients receiving ELREXFIO are at risk of depressed level of consciousness. Advise patients not to drive or operate heavy or potentially dangerous machinery for 48 hours after completing each of the 2 step-up doses and the first treatment dose within the ELREXFIO step-up dosing schedule and in the event of new onset of any neurological toxicity symptoms until symptoms resolve [see Dosage and Administration (2.2)].

ELREXFIO is available only through a restricted program under a REMS [see Warnings and Precautions (5.3)].

ELREXFIO REMS

ELREXFIO is available only through a restricted program under a REMS called the ELREXFIO REMS because of the risks of CRS and neurologic toxicity, including ICANS [see Warnings and Precautions (5.1, 5.2)].

Notable requirements of the ELREXFIO REMS include the following:

•: Prescribers must be certified with the program by enrolling and completing training.
•: Prescribers must counsel patients receiving ELREXFIO about the risk of CRS and neurologic toxicity, including ICANS, and provide patients with ELREXFIO Patient Wallet Card.
•: Pharmacies and healthcare settings that dispense ELREXFIO must be certified with the ELREXFIO REMS program and must verify prescribers are certified through the ELREXFIO REMS program.
•: Wholesalers and distributers must only distribute ELREXFIO to certified pharmacies or healthcare settings.

Further information about the ELREXFIO REMS program is available at www.ELREXFIOREMS.com or by telephone at 1‑844‑923‑7845.

Infections

ELREXFIO can cause severe, life-threatening, or fatal infections. In the clinical trial, in patients who received ELREXFIO according to the recommended dosing schedule, serious infections, including opportunistic infections, occurred in 42% of patients, with Grade 3 or 4 infections in 31%, and fatal infections in 7%. The most common serious infections reported (≥5%) were pneumonia and sepsis [see Adverse Reactions (6.1)].

Do not initiate treatment with ELREXFIO in patients with active infections. Monitor patients for signs and symptoms of infection prior to and during treatment with ELREXFIO and treat appropriately. Withhold or permanently discontinue ELREXFIO based on severity [see Dosage and Administration (2.5)]. Administer prophylactic antimicrobial and anti-viral medications according to current practice guidelines. Consider treatment with subcutaneous or intravenous immunoglobulin (IVIG) as appropriate.

Neutropenia

ELREXFIO can cause neutropenia and febrile neutropenia. In patients who received ELREXFIO at the recommended dose in the clinical trial, decreased neutrophils occurred in 62% of patients, with Grade 3 or 4 decreased neutrophils in 51%. Febrile neutropenia occurred in 2.2% of patients [see Adverse Reactions (6.1)].

Monitor complete blood cell counts at baseline and periodically during treatment. Provide supportive care according to current practice guidelines. Monitor patients with neutropenia for signs of infection. Withhold ELREXFIO based on severity [see Dosage and Administration (2.5)].

Hepatotoxicity

ELREXFIO can cause hepatotoxicity. In the clinical trial, elevated ALT occurred in 36% of patients, with Grade 3 or 4 ALT elevation occurring in 3.8%; elevated AST occurred in 40% of patients, with Grade 3 or 4 AST elevation occurring in 6%. Grade 3 or 4 total bilirubin elevations occurred in 0.5% of patients [see Adverse Reactions (6.1)]. Liver enzyme elevation can occur with or without concurrent CRS.

Monitor liver enzymes and bilirubin at baseline and during treatment as clinically indicated. Withhold ELREXFIO or consider permanent discontinuation of ELREXFIO based on severity [see Dosage and Administration (2.5)].

Embryo-Fetal Toxicity

Based on its mechanism of action, ELREXFIO may cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to the fetus. Advise females of reproductive potential to use effective contraception during treatment with ELREXFIO and for 4 months after the last dose [see Use in Specific Populations (8.1, 8.3)].

The following adverse reactions are discussed elsewhere in labeling:

•: Cytokine Release Syndrome [see Warnings and Precautions (5.1)].
•: Neurologic Toxicity, Including ICANS [see Warnings and Precautions (5.2)].
•: Infections [see Warnings and Precautions (5.4)].
•: Neutropenia [see Warnings and Precautions (5.5)].
•: Hepatotoxicity [see Warnings and Precautions (5.6)].

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Relapsed/Refractory Multiple Myeloma

MagnetisMM-3

The safety of ELREXFIO was evaluated in MagnetisMM-3 [see Clinical Studies (14)]. The safety population described (n = 183) includes patients who received the recommended dosage regimen of 12 mg subcutaneously on Day 1, 32 mg on Day 4, and 76 mg once weekly starting on Day 8. Among patients who received ELREXFIO, 42% were exposed for 6 months or longer and 9% were exposed for one year or longer.

The median age of patients who received ELREXFIO was 68 years (range: 36 to 88 years); 48% were female; 61% were White, 10% were Hispanic/Latino, 9% were Asian, and 6% were Black or African American.

Serious adverse reactions occurred in 68% of patients who received ELREXFIO at the recommended dosing schedule. Serious adverse reactions in >2% of patients included pneumonia (25%), sepsis (13%), CRS (13%), upper respiratory tract infection (4.4%), acute kidney injury (3.8%), urinary tract infection (3.3%), COVID-19 (3.3%), encephalopathy (3.3%), pyrexia (2.2%), and febrile neutropenia (2.2%). Fatal adverse reactions occurred in 10% of patients including pneumonia (3.3%), sepsis (2.7%), acute respiratory distress syndrome (0.5%), cardio-respiratory arrest (0.5%), cardiogenic shock (0.5%), cardiopulmonary failure (0.5%), COVID-19 (0.5%), failure to thrive (0.5%), and pulmonary embolism (0.5%).

Permanent discontinuations of ELREXFIO due to an adverse reaction occurred in 17% of patients. Adverse reactions which resulted in permanent discontinuation of ELREXFIO in >2% of patients included septic shock (2.2%).

Dosage interruptions of ELREXFIO due to an adverse reaction occurred in 73% of patients. Adverse reactions which resulted in dose interruptions of ELREXFIO in >5% of patients included neutropenia, pneumonia, COVID-19, upper respiratory tract infection, thrombocytopenia, and anemia.

The most common adverse reactions (≥20%) were CRS, fatigue, injection site reaction, diarrhea, upper respiratory tract infection, musculoskeletal pain, pneumonia, decreased appetite, rash, cough, nausea, and pyrexia. The most common Grade 3 to 4 laboratory abnormalities (≥30%) were decreased lymphocytes, decreased neutrophils, decreased hemoglobin, decreased white blood cells, and decreased platelets.

Table 8 summarizes adverse reactions in MagnetisMM-3.

Table 8. Adverse Reactions (≥10%) in Patients with Relapsed or Refractory Multiple Myeloma Who Received ELREXFIO in MagnetisMM-3
Adverse reactions were graded based on CTCAE Version 5.0, with the exception of CRS, which was graded based on the ASTCT 2019 criteria.
* Only grade 3 adverse reactions occurred. † Includes other related terms. ‡ Pneumonia includes COVID-19 pneumonia, lower respiratory tract infection, lower respiratory tract infection viral, pneumocystis jirovecii pneumonia, pneumonia, pneumonia adenoviral, pneumonia bacterial, pneumonia cytomegaloviral, pneumonia fungal, pneumonia influenzal, pneumonia pseudomonal, pneumonia viral. § Sepsis includes bacteremia, device related bacteremia, device related sepsis, escherichia bacteremia, escherichia sepsis, klebsiella sepsis, pseudomonal sepsis, sepsis, septic shock, staphylococcal bacteremia, staphylococcal sepsis, streptococcal sepsis, urosepsis. ¶ Rash incudes erythema, palmar-plantar erythrodysesthesia syndrome, rash, rash erythematous, rash macular, rash maculo-papular, rash pustular, symmetrical drug-related intertriginous and flexural exanthema. # Encephalopathy includes agitation, altered state of consciousness, cognitive disorder, confusional state, delirium, depressed level of consciousness, disorientation, hallucination, lethargy, memory impairment, mental status changes, metabolic encephalopathy, somnolence, toxic encephalopathy. Þ Sensory neuropathy includes burning sensation, dysesthesia, hypoesthesia, neuropathy peripheral, paresthesia, parosmia, peripheral sensorimotor neuropathy, peripheral sensory neuropathy, polyneuropathy, sensory loss. ß Motor dysfunction includes ataxia, balance disorder, gait disturbance, motor dysfunction, muscle contracture, muscle spasms, muscular weakness, peripheral motor neuropathy, peroneal nerve palsy, tremor.
System Organ Class Preferred Term	ELREXFIO N = 183
	All Grades (%)	Grade 3 or 4 (%)
Immune system disorders
Cytokine release syndrome	58	0.5 *
Hypogammaglobulinemia †	13	2.2 *
General disorders and site administration conditions
Fatigue †	43	6 *
Injection site reaction †	37	0
Pyrexia	21	2.7 *
Edema †	18	1.1 *
Gastrointestinal disorders
Diarrhea	36	1.1 *
Nausea	22	0
Constipation	15	0
Vomiting	14	0
Infections
Upper respiratory tract infection †	34	4.9
Pneumonia ‡	32	19
Sepsis §	15	11
Urinary tract infection †	12	4.4 *
Musculoskeletal and connective tissue disorders
Musculoskeletal pain †	34	2.7 *
Metabolism and nutrition disorders
Decreased appetite	26	1.1 *
Skin and Subcutaneous Tissue disorders
Rash ¶	25	0
Dry skin	13	0
Skin exfoliation †	10	0
Respiratory, thoracic and mediastinal disorders
Cough †	24	0
Dyspnea †	15	3.3 *
Nervous system disorders
Headache	18	0.5
Encephalopathy #	15	2.7
Sensory neuropathy Þ	13	0.5 *
Motor dysfunction ß	13	2.2 *
Cardiac disorders
Cardiac arrhythmia †	16	2.2
Vascular disorders
Hemorrhage †	13	1.6
Psychiatric disorders
Insomnia	13	0
Injury, poisoning and procedural complications
Fall	10	0.5 *

Clinically relevant adverse reactions in <10% of patients who received ELREXFIO included ICANS, febrile neutropenia, Guillain-Barré syndrome, abdominal pain, acute kidney injury, COVID-19, cardiac failure, congestion, and thrombosis.

Table 9 summarizes laboratory abnormalities in MagnetisMM-3.

Table 9. Select Laboratory Abnormalities (≥30%) That Worsened from Baseline in Patients with Relapsed or Refractory Multiple Myeloma Who Received ELREXFIO in MagnetisMM-3 *
* Laboratory tests were graded according to NCI-CTCAE Version 5.0 † The denominator used to calculate the rate varied from 181 to 183 based on the number of patients with a baseline value and at least one post-treatment value.
Laboratory Abnormality	ELREXFIO †
Laboratory Abnormality	All Grades (%)	Grade 3 or 4 (%)
Hematology
Lymphocyte count decreased	91	84
White blood cell decreased	69	40
Hemoglobin decreased	68	43
Neutrophil count decreased	62	51
Platelet count decreased	61	32
Chemistry
Albumin decreased	55	6
AST increase	40	6
Creatinine increased	38	3.3
Potassium decreased	36	8
ALT increase	36	3.8
Alkaline phosphatase increased	34	1.1
Creatinine clearance decreased	32	10

For certain CYP substrates, minimal changes in the concentration may lead to serious adverse reactions. Monitor for toxicity or drug concentrations of such CYP substrates when co-administered with ELREXFIO.

ELREXFIO causes release of cytokines [see Clinical Pharmacology (12.2)] that may suppress activity of cytochrome P450 (CYP) enzymes, resulting in increased exposure of CYP substrates. Increased exposure of CYP substrates is more likely to occur after the first dose of ELREXFIO Day 1 and up to 14 days after the 32 mg dose on Day 4 and during and after CRS [see Warnings and Precautions (5.1)].

Elranatamab-bcmm is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager. It is a bispecific, humanized immunoglobulin 2-alanine (IgG2Δa) kappa antibody derived from two monoclonal antibodies (mAbs), an anti-BCMA mAb and an anti-CD3 mAb. Each of these mAbs contributes one distinct heavy (H) chain and one distinct light (L) chain to the bispecific elranatamab-bcmm. The resulting 4-chain bispecific antibody is covalently linked via five inter-chain disulfide bonds. Elranatamab-bcmm is produced using two recombinant Chinese hamster ovary (CHO) cell lines, one that contains the DNA encoding the sequence for anti-BCMA monoclonal antibody (mAb) and one that contains the sequence for anti-CD3 mAb, which are grown separately in suspension culture using chemically-defined (CD), animal-derived component-free (ACF) media. The molecular weight of elranatamab-bcmm is approximately 148.5 kDa.

ELREXFIOTM (elranatamab-bcmm) injection is a sterile, preservative-free, clear to slightly opalescent, and colorless to pale brown liquid solution for subcutaneous administration. ELREXFIO (elranatamab-bcmm) is supplied at a concentration of 40 mg/mL in either 76 mg/1.9 mL or 44 mg/1.1 mL single-dose vials. Each mL of solution contains 40 mg elranatamab-bcmm, edetate disodium (0.045 mg), histidine (1.12 mg), L-histidine hydrochloride monohydrate (2.67 mg), polysorbate 80 (0.2 mg), sucrose (85 mg) and Water for Injection. The pH is 5.8.

Mechanism of Action

Elranatamab-bcmm is a bispecific B-cell maturation antigen (BCMA)-directed T-cell engaging antibody that binds BCMA on plasma cells, plasmablasts, and multiple myeloma cells and CD3 on T-cells leading to cytolysis of the BCMA-expressing cells. Elranatamab-bcmm activated T-cells, caused proinflammatory cytokine release, and resulted in multiple myeloma cell lysis.

Pharmacodynamics

Cytokine Concentrations

Transient elevation of circulating cytokines IL-2, IL-6, IL-8, IL-10, TNF-α, and IFN-γ was observed at dosage levels of 30 µg/kg (0.03 times the approved recommended dosage) and above. After administration of the approved recommended dosage of ELREXFIO, the highest elevation of cytokines was generally observed within 72 hours after first elranatamab-bcmm dose at 12 mg on Day 1, and generally returned to baseline prior to the administration of the first full dose 76 mg on Day 8.

Pharmacokinetics

Pharmacokinetic parameters are presented as geometric mean (coefficient of variation [CV]%) and are based upon subcutaneously administered unless otherwise specified.

Elranatamab-bcmm exhibits dose proportional pharmacokinetics over dose range from 6 to 76 mg (0.079 to 1 times the approved recommended dosage). Elranatamab-bcmm maximum concentration [33.6 mcg/mL (48%)] is achieved at the end of weekly dosing regimen (i.e., at week 24 of 76 mg weekly dosing). Pharmacokinetic exposures are summarized for the recommended dosage of ELREXFIO in Table 10.

Table 10. Pharmacokinetic Parameters of Elranatamab-bcmm in Subjects with Relapsed or Refractory Multiple Myeloma
* In patients who have achieved a response. † Steady state exposure of elranatamab biweekly dose is approximated at week 48.
Timepoint	Parameters
Timepoint	Cavg (mcg/mL)	Cmax (mcg/mL)	Ctrough (mcg/mL)
First full 76 mg dose	3.1 (94%)	3.8 (94%)	3.3 (102%)
End of weekly dose (week 24) *	32.7 (49%)	33.6 (48%)	31.2 (50%)
Steady state (biweekly dosing) * †	18.4 (57%)	20.1 (55%)	15.9 (64%)

Absorption

The mean bioavailability of elranatamab-bcmm was 56.2% when administered subcutaneously. The median (min, max) Tmax after elranatamab SC administration was 7 (3 to 7) days.

Distribution

The steady state volume of distribution of elranatamab-bcmm was 7.76 L (33%).

Elimination

The half-life of elranatamab-bcmm is 22 (64%) days at the 76 mg dosage, with clearance of 0.324 L/day (100%) following 24 weeks dosing.

Metabolism

Elranatamab-bcmm is expected to be metabolized into small peptides by catabolic pathways.

Specific Populations

No clinically significant differences in the pharmacokinetics of elranatamab-bcmm were observed based on age (36 to 89 years), sex, race (White, Asian, or Black), body weight (37 to 160 kg), mild or moderate renal impairment (estimated glomerular filtration rate [eGFR] by Modification of Diet in Renal Disease [MDRD] method: 30 to 89 mL/min), or mild hepatic impairment (total bilirubin 1 to ≤1.5 x ULN or any AST greater than ULN).

The effects of severe renal impairment (eGFR 15 to 29 mL/min), end-stage renal disease (eGFR <15 mL/min), or moderate to severe hepatic impairment (total bilirubin >1.5 times ULN and any AST) on the PK of elranatamab-bcmm are unknown.

Immunogenicity

The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of elranatamab-bcmm or of other elranatamab products.

In the MagnetisMM-3 study, of the 168 participant who received recommended step-up and full dosage of ELREXFIO for up to 24 month and are evaluable for presence of ADA against elranatamab-bcmm, 8.9% (15/168) of patients tested positive for anti-elranatamab-bcmm-antibodies. Among the 15 patients who tested positive for ADAs, 60% (9/15) tested positive for neutralizing antibodies against elranatamab-bcmm. The effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of ELREXFIO products is unknown.

Relapsed or Refractory Multiple Myeloma

The efficacy of ELREXFIO monotherapy was evaluated in patients with relapsed or refractory multiple myeloma in an open-label, single arm, multi-center study (MagnetisMM-3, NCT04649359). The study included patients who were refractory to at least one proteasome inhibitor (PI), one immunomodulatory agent (IMiD), and one anti-CD38 monoclonal antibody. MagnetisMM-3 included 123 patients naïve to prior BCMA-directed therapy (pivotal Cohort A) and 64 patients with prior BCMA-directed antibody drug conjugate (ADC) or chimeric antigen receptor (CAR) T-cell therapy (supportive Cohort B). Patients had measurable disease by International Myeloma Working Group (IMWG) criteria at enrollment. The study included patients with an Eastern Cooperative Oncology Group (ECOG) score of ≤2, adequate baseline bone marrow (absolute neutrophil count ≥1.0 x 109/L, platelet count ≥25 x 109/L, hemoglobin level ≥8 g/dL), renal (CrCL ≥ 30 mL/min), and hepatic (AST and ALT ≤2.5 x ULN, total bilirubin ≤2 x ULN) function, and left-ventricular ejection fraction ≥40%. Patients with a stem cell transplant within 12 weeks prior to enrollment and active infections were excluded from the study.

Eligible patients received subcutaneous administration of ELREXFIO at step-up doses of 12 mg on Day 1 and 32 mg on Day 4 of treatment, followed by the first treatment dose of ELREXFIO (76 mg) on Day 8 of treatment. Thereafter, patients received 76 mg once weekly. After 24 weeks, in patients who achieved an IMWG response category of partial response or better with responses persisting for at least 2 months, the dose interval was changed from every week to every 2 weeks.

The 123 patients enrolled in pivotal Cohort A had received a median of 5 prior lines of therapy (range: 2 to 22). Ninety-seven patients who were not exposed to prior BCMA-directed therapy and received at least four prior lines of therapy comprised the efficacy population. Among the 97 patients in the efficacy population, the median age was 69 (range: 46 to 89) years with 18.6% of patients ≥75 years of age. Forty percent were female; 59.8% were White, 13.4% were Asian, 7.2% were Hispanic/Latino, 5.2% were Black or African American. Disease stage (R-ISS) at study entry was 20.6% in Stage I, 53.6% in Stage II, and 17.5% in Stage III. The median time since initial diagnosis of multiple myeloma to enrollment was 79.6 (range: 16 to 228) months. 96.9% were triple-class refractory, and 94.8% were refractory to their last line of therapy. 69.1% received prior autologous stem cell transplantation, and 7.2% received prior allogenic stem cell transplantation. High-risk cytogenetics [t(4;14), t(14;16), or del(17p)] were present in 22.7% of patients. 34.0% of patients had extramedullary disease at baseline by BICR.

Efficacy was based on response rate and duration of response (DOR), as assessed by BICR based on IMWG criteria. Efficacy results from BCMA-directed therapy naïve patients are shown in Table 11.

The median (range) time to first response (TTR) was 1.22 (0.9 to 6.5) months. With a median follow-up of 11.1 months (95% CI: 10.6, 12.0) among responders, the DOR rate at 6 months was 90.4% (95% CI: 78.4%, 95.9%) and at 9 months was 82.3% (95% CI: 67.1%, 90.9%).

Table 11. Efficacy Results from BCMA-directed Therapy Naïve Patients
Abbreviations: CI = Confidence interval; NR = Not reached; NE = Not estimable.
* Complete response or better = Stringent complete response (sCR) + complete response (CR).
	N = 97
Objective Response Rate (ORR: sCR+CR+VGPR+PR), n (%) (95% CI)	56 (57.7%) (47.3, 67.7)
Complete response (CR) or better *	25 (25.8%)
Very good partial response (VGPR)	25 (25.8%)
Partial response (PR)	6 (6.2%)
Duration of Response (DOR) (months) Median (95% CI)	NR (12.0, NE)

Among the 64 patients enrolled in Cohort B who previously received a PI, an IMiD, an anti-CD38 monoclonal antibody, and a BCMA-directed therapy, 63 patients received at least four prior lines of therapy. Patients had received a median of 8 prior lines of therapy (range: 4 to 19); 73% and 32% received prior BCMA-directed ADC and CAR T-cell therapy, respectively.

Confirmed ORR by BICR was 33.3% (95% CI: 22.0, 46.3). After a median (95% CI) follow-up of 10.2 (9.9, 11.0) months among responders, median DOR was not reached (95% CI: NE, NE) and the DOR rate at 9 months was 84.3% (95% CI: 58.7, 94.7).

How Supplied

ELREXFIOTM (elranatamab-bcmm) injection is a sterile, preservative-free, clear to slightly opalescent, and colorless to pale brown liquid solution supplied as follows:

•: One 76 mg/1.9 mL (40 mg/mL) single-dose vial in a carton. NDC: 0069-4494-02
•: One 44 mg/1.1 mL (40 mg/mL) single-dose vial in a carton. NDC: 0069-2522-02

ELREXFIO is supplied in a single-dose glass vial sealed with a rubber stopper (not made of natural rubber latex) and an aluminum seal with a flip-off cap.

Storage and Handling

Store refrigerated at 2 °C to 8 °C (36 °F to 46 °F) in the original carton until time of use to protect from light.

Do not freeze or shake the vial or carton.

View less

Contact Medical Science Liaison

Report Adverse Event

Elrexfio

Dosage & Administration

Elrexfio Prescribing Information

Important Dosing Information

Recommended Dosage

Recommended Pre-treatment Medications

Restarting ELREXFIO After Dosage Delay

Dosage Modifications for Adverse Reactions

Preparation and Administration Instructions

Pregnancy

Lactation

Females and Males of Reproductive Potential

Pediatric Use

Geriatric Use

Cytokine Release Syndrome (CRS)

Neurologic Toxicity, Including Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS)

ELREXFIO REMS

Infections

Neutropenia

Hepatotoxicity

Embryo-Fetal Toxicity

Clinical Trials Experience

Mechanism of Action

Pharmacodynamics

Pharmacokinetics

Immunogenicity

Carcinogenesis, Mutagenesis, Impairment of Fertility

Relapsed or Refractory Multiple Myeloma

Mechanism of Action

Elrexfio Prior Authorization Resources

Benefits investigation

Reimbursement help (FRM)

Elrexfio PubMed™ News